TITLE

US Senate passes FDA Revitalization Act

AUTHOR(S)
Guthrie, Patricia
PUB. DATE
July 2007
SOURCE
CMAJ: Canadian Medical Association Journal;7/3/2007, Vol. 177 Issue 1, p23
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article reports on the new U.S. legislation passed by the senate that would strengthen the Food and Drug Administration's (FDA) ability to scrutinize new and existing drugs. The report says the bill sponsored by Senators Edward Kennedy and Mike Enzi obligates the government to establish a market surveillance system to track the adverse effects of drugs and to create a public database of clinical trial results. It also renews FDA authority to collect fees from drug companies to speed reviews.
ACCESSION #
25625518

 

Related Articles

  • Bill proposes risk plan for all approvals. J. G. D. // Medical Marketing & Media;Sep2006, Vol. 41 Issue 9, p17 

    The article reports on a proposed drug safety legislation that would require each drug and biologic approved by the United States Food and Drug Administration to have a Risk Evaluation and Mitigation Strategy. Senate Health, Education, Labor and Pensions Committee Chairman Mike Enzi and Democrat...

  • Bipartisan bill elevates drug safety oversight.  // Drug Store News;9/11/2006, Vol. 28 Issue 11, p34 

    No abstract available.

  • Biologics: Senate bill proposes follow-on pathway.  // PharmaWatch: Biotechnology;Aug2007, Vol. 6 Issue 8, p9 

    The article reports on the introduction of the Biologics Price Competition and Innovation Act of 2007 (Senate bill S 623) by Senators Edward Kennedy, Michael Enzi, Hilary Clinton, and Orrin Hatch in the U.S. The bill allows the Food and Drug Administration (FDA) to approve follow-on biologics...

  • Sens. Kennedy and Enzi present drug safety bill. J. G. D. // Medical Marketing & Media;Mar2007, Vol. 42 Issue 3, p14 

    The article reports that Senators Edward Kennedy and Mike Enzi have re-introduced their Enhancing Drug Safety and Innovation Act which requires better safety planning prior to drug approval in the U.S. The legislative bill also calls for improvement in the response of the Food and Drug...

  • Bill Calls for More Drug Oversight.  // Pharmaceutical Executive;Sep2006, Vol. 26 Issue 9, p28 

    The article focuses on the disclosure of bill to be improved by the Food and Drug Administration (FDA) oversight of drug safety after the negotiations of Senators Michael Enzi and Edward Kennedy in the U.S. The bill clarifies FDA authority to require risk management plans. It also requires...

  • Senators offer drug safety options. Wechsler, Jill // Managed Healthcare Executive;Sep2006, Vol. 16 Issue 9, p10 

    The article reports that Senators Michael Enzi of Wyoming and Edward Kennedy of Massachusetts presented a bill that provides for the improvement of the FDA's campaign for drug safety. The bill called S. 3807 covers registration and results disclosure of clinical trails, support for Critical Path...

  • Legislation in the Works.  // HealthFacts;May2007, Vol. 32 Issue 5, p3 

    The article reports that the Safe Drug Compounding Act of 2007 is due to be introduced by Senators Edward Kennedy and Richard Burr. Along with several other consumer and women's advocacy organizations, the Center for Medical Consumers has signed a letter of support for this law which would...

  • Stage set for Senate to shackle DTC advertisers. Teinowitz, Ira // Advertising Age;2/26/2007, Vol. 78 Issue 9, p43 

    The article states that the U.S. Senate's health committee has set a tentative date to consider legislation from Senator Ted Kennedy of Massachusetts and Senator Michael Enzi of Wyoming that could dramatically restrict direct-to-consumer advertising for prescription drugs. Advertising groups...

  • Drug Ads Survive.  // Multinational Monitor;Mar/Apr2007, Vol. 28 Issue 2, p52 

    The article announces that pharmaceutical companies have escaped restrictions on the ability to market directly to consumers in the U.S. Senators Ted Kennedy of Massachusetts and Michael Enzi of Wyoming proposed adding a limitation to a U. S. Food and Drug Administration (FDA) funding bill that...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics